Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluticasone propionate + salmeterol (Pfizer)
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
PF-04764793 is an inhaled combination therapy developed by Pfizer for the treatment of asthma. It consists of fluticasone propionate, a synthetic corticosteroid that acts as a glucocorticoid receptor agonist to reduce airway inflammation, and salmeterol xinafoate, a long-acting beta2-adrenergic receptor agonist (LABA) that promotes bronchodilation. This combination is intended to provide both anti-inflammatory and bronchodilatory effects, similar to the established therapy Advair. Pfizer conducted Phase 1 clinical trials (such as NCT01041391) to evaluate the pharmacokinetics of PF-04764793 when delivered via different dry powder inhaler (DPI) designs in healthy volunteers.
- Brand names
- Wixela InhubAirFluSal ForspiroStalmotide
- Other names
- fluticasone propionate/salmeterol xinafoate
02
Targets
GR (Glucocorticoid receptor)ADRB2 (β2)
Beyond the preview
Go deeper on fluticasone propionate + salmeterol (Pfizer).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluticasone propionate + salmeterol (Pfizer).